Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women

Table 4 Incremental cost-effectiveness results

Intervention n	Average cost (€)	Performance ^a (%)	∆ Cost (€)	∆ Performance^a (%)	ICER ∆ Cost / ∆ Performance^a
Based on costs related to RHD status (tests, anti-D injections and visits)
Usual care	452	64%
RHD genotyping	591	88%	139	24%	578

^a Performance is defined as the percentage of RHD negative women receiving appropriate management

ISSN: 1471-2393